Company · Dublin, Dublin, Ireland
Noden Pharma Dac
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 6
- 0 authorized now
- Natural health products
- 0
- 0 active licences
- Medical device licences
- 0
- 0 active
- Notices of Compliance
- 4
Drug products
Authorized products first.
| Name | DIN | Status | Status since |
|---|---|---|---|
| RASILEZStatus since Mar 2024 | 02302063 | Cancelled Post Market | |
| RASILEZStatus since Aug 2023 | 02302071 | Cancelled Post Market | |
| RASILEZ HCTStatus since Feb 2020 | 02332728 | Cancelled Post Market | |
| RASILEZ HCTStatus since Feb 2020 | 02332736 | Cancelled Post Market | |
| RASILEZ HCTStatus since Feb 2020 | 02332744 | Cancelled Post Market | |
| RASILEZ HCTStatus since Feb 2020 | 02332752 | Cancelled Post Market |
Notices of Compliance
Newest first.
- RASILEZApril 30, 2021 · NOC 25770 · Supplement to a New Drug Submission (SNDS)
- RASILEZ HCTJuly 8, 2019 · NOC 22375 · Supplement to a New Drug Submission (SNDS)
- RASILEZ HCTJanuary 17, 2018 · NOC 20366 · New Drug Submission (NDS)
- RASILEZJanuary 12, 2018 · NOC 20304 · New Drug Submission (NDS)
Recalls and safety alerts that mention its products
Health Canada’s recall notices do not carry licence numbers, so these are matched by name. A notice may cover another product or only some lots: read it to see what it covers.
- RasilezMay 28, 2013 · Drugs · Product safety · Type III
- RASILEZ (aliskiren) and RASILEZ HCT (aliskiren/hydrochlorothiazide) - Potential Risks of Cardiovascular and Renal Adverse Events in Patients with Type 2 Diabetes - For Health ProfessionalsJanuary 23, 2012 · Drugs
- RASILEZ (aliskiren) and RASILEZ HCT (aliskiren/hydrochlorothiazide) - Potential Risks of Cardiovascular and Renal Adverse Events in Patients with Type 2 Diabetes - For the PublicJanuary 23, 2012 · Drugs
- Rasilez (aliskiren): Health Canada reviewing safety of blood-pressure drugDecember 22, 2011 · Drugs · Product safety